A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia

This is a randomized, double-blind, multi-center, therapeutic confirmatory, phase 3 trial to evaluate the efficacy and safety of CKD-391 and CKD-331 in patients with primary hypercholesterolemia

Inclusion Criteria:Adults ≥ 19 years of agePrimary hypercholesterolemiaPatients willing and able to discontinue ongoing lipid-lowering therapy according to the opinion of the investigatorExclusion Criteria:Secondary hypercholesterolemiaConditions / situations such as:Presence of any clinically significant uncontrolled endocrine/metabolic disease known to influence lipids levelsSevere renal impairment or active liver diseaseHistory of hypersensitivity or allergies to investigational drugs or drug of similar chemical classes.History of drug abuse or alcoholism within 24 weeks before screeningAny surgical or medical condition which might significantly affect the absorption, distribution, metabolism, or excretion of investigational drugsPatients who have been taken with other investigational drugs within 8 weeks before screening